Obinutuzumab is an anti-CD20 antibody used to treat chronic lymphocytic leukemia, follicular lymphoma, and lupus nephritis. Obinutuzumab is a humanized anti-CD20 monoclonal antibody designed to treat B-cell malignancies.
- Mechanism
- Curator reviewed · 10 references
Obinutuzumab is a CD20-directed cytolytic antibody. It targets the CD20 antigen, a molecule expressed on pre-B and mature B lymphocytes. Obinutuzumab mediates B-cell lysis via three mechanisms: engagement of immune effector cells, direct activation of intracellular death signaling pathways, and activation of the complement cascade. Immune effector cell mechanisms include antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis. Obinutuzumab, with its reduced fucose content, exhibits greater ADCC activity than rituximab in vitro. It also induces direct cell death more effectively than rituximab and binds to FcγRIII with a higher affinity than rituximab.
- Primary indication
- Obinutuzumab, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).Curator reviewed · 7 structured indications
- Formula / weight
- C6512H10060N1712O2020S44 · 150000.0 Da (approximate)
- First approval
- Canada, 2014 · United States, 2013 · European Union, 2020
- Also known as
- Afutuzumab · Anti-CD20 monoclonal antibody R7159 · IMMUNOGLOBULIN G1, ANTI-(HUMAN CD20 (ANTIGEN)) (HUMAN-MOUSE MONOCLONAL GA101 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL GA101 .KAPPA.-CHAIN, DIMER · IMMUNOGLOBULIN G1, ANTI-(HUMAN CD20 (ANTIGEN)) (HUMAN-MOUSE MONOCLONAL GA101 HEAVY CHAIN), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL GA101 .KAPPA.-CHAIN, DIMER
- Code names
- GA-101 · R-7159 · RG7159 · RO-5072759
- Brand names
Resolves to
What you can answer from here — as of November 05, 2025
Which drugs share a target with Obinutuzumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account